von Willebrand factor propeptide: biology and clinical utility

被引:63
|
作者
Haberichter, Sandra L. [1 ,2 ,3 ]
机构
[1] BloodCtr Wisconsin, Diagnost Labs, Milwaukee, WI 53201 USA
[2] BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI 53201 USA
[3] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA
基金
美国国家卫生研究院;
关键词
VONWILLEBRAND-FACTOR VWF; WEIBEL-PALADE BODIES; ANTIGEN-II; DEFECTIVE MULTIMERIZATION; ENDOTHELIAL DYSFUNCTION; REGULATED SECRETION; FACTOR SURVIVAL; FACTOR STORAGE; PLASMA-LEVELS; FACTOR-VIII;
D O I
10.1182/blood-2015-04-512731
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand factor (VWF) is a large multimeric glycoprotein that mediates the attachment of platelets to damaged endothelium and also serves as the carrier protein for coagulation factor VIII (FVIII), protecting it from proteolytic degradation. Quantitative or qualitative defects in VWF result in von Willebrand disease (VWD), a common inherited bleeding disorder. VWF is synthesized with a very large propeptide (VWFpp) that is critical for intracellular processing of VWF. VWFpp actively participates in the process of VWF multimerization and is essential for trafficking of VWF to the regulated storage pathway. Mutations identified within VWFpp in VWD patients are associated with altered VWF structure and function. The assay of plasma VWFpp has clinical utility in assessing acute and chronic vascular perturbation associated with diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabetes among others. VWFpp assay also has clear utility in the diagnosis of VWD subtypes, particularly in discriminating true type 3 subjects from type 1C (reduced plasma survival of VWF), which is clinically important and has implications for therapeutic treatment.
引用
收藏
页码:1753 / 1761
页数:9
相关论文
共 50 条
  • [1] Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome
    Stufano, Francesca
    Boscarino, Marco
    Bucciarelli, Paolo
    Baronciani, Luciano
    Maino, Alberto
    Cozzi, Giovanna
    Peyvandi, Flora
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (01): : 36 - 42
  • [2] Von Willebrand factor and its propeptide
    Lenting, P. J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 10 - 10
  • [3] von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease
    Sanders, Yvonne V.
    Groeneveld, Dafna
    Meijer, Karina
    Fijnvandraat, Karin
    Cnossen, Marjon H.
    van der Bom, Johanna G.
    Coppens, M.
    de Meris, Joke
    Laros-van Gorkom, Britta A. P.
    Mauser-Bunschoten, Eveline P.
    Leebeek, Frank W. G.
    Eikenboom, Jeroen
    [J]. BLOOD, 2015, 125 (19) : 3006 - 3013
  • [4] Functional Roles of the von Willebrand Factor Propeptide
    Rawley, Orla
    Lillicrap, David
    [J]. HAMOSTASEOLOGIE, 2021, 41 (01): : 63 - 68
  • [5] Von Willebrand factor propeptide in vascular disorders
    van Mourik, JA
    de Wit, TR
    [J]. THROMBOSIS AND HAEMOSTASIS, 2001, 86 (01) : 164 - 171
  • [6] Assessment of von Willebrand Factor Propeptide Improves the Diagnosis of von Willebrand Disease
    Casonato, Alessandra
    Daidone, Viviana
    Padrini, Roberto
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2011, 37 (05): : 456 - 463
  • [7] Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status
    Lee, Adrienne
    Sinclair, Gary
    Valentine, Karen
    James, Paula
    Poon, Man-Chiu
    [J]. BLOOD, 2014, 124 (05) : E1 - E3
  • [8] Quantification of von Willebrand Factor and von Willebrand Factor Propeptide in Patients with End Stage Renal Disease
    Davis, Rachael
    Bansal, Vinod
    Litinas, Evangelos
    Rahman, Saudur
    Hoppensteadt, Debra
    Conway, Brooke
    Fareed, Jawed
    [J]. FASEB JOURNAL, 2010, 24
  • [9] On the cutting edge: von Willebrand factor propeptide and thrombosis
    Ragni, M. V.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (12) : 2553 - 2555
  • [10] von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease
    Vischer, UM
    de Moerloose, P
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 30 (02) : 93 - 109